Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 39 results:
Συντάκτης [ Τίτλος] Τύπος Έτος Φίλτρα: Συντάκτης is Terpos, Evangelos [Clear All Filters]
Wnt/beta-catenin signaling inhibitors and nonalcoholic fatty liver disease: Potential therapeutic implications..
Hepatobiliary Pancreat Dis Int.
(2023). Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid..
Support Care Cancer. 17(10), 1329-30.
(2009).
(2014). Serum osteoprotegerin, RANKL, and Dkk-1 levels in adults with Langerhans cell histiocytosis..
J Clin Endocrinol Metab. 97(4), E618-21.
(2012). Is serum IL-17A a useful systemic biomarker in patients with Langerhans cell histiocytosis?.
Mol Ther. 20(1), 6-7.
(2012). Serum homocysteine, folate and vitamin B12 in patients with Paget's disease of bone: the effect of zoledronic acid..
J Bone Miner Metab. 28(3), 314-9.
(2010). Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy..
Am J Hematol. 92(7), 632-639.
(2017). Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group..
Blood Cancer J. 8(3), 31.
(2018). Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival..
Ann Hematol. 97(9), 1671-1682.
(2018). RANKL inhibition for the management of patients with benign metabolic bone disorders..
Expert Opin Investig Drugs. 18(8), 1085-102.
(2009). Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease..
J Bone Miner Metab. 28(6), 706-12.
(2010). Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia..
Leuk Lymphoma. 58(6), 1506-1508.
(2017). Periostin and sclerostin levels in juvenile Paget's disease..
Clin Cases Miner Bone Metab. 14(2), 269-271.
(2017). Paget's disease of bone: emphasis on treatment with zoledronic acid..
Expert Rev Endocrinol Metab. 4(5), 423-434.
(2009). A novel noninvasive index for nonalcoholic steatohepatitis: a pilot study..
Biomarkers. 18(7), 607-13.
(2013). Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid..
Endokrynol Pol. 63(4), 312-5.
(2012). Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment..
Hormones (Athens). 17(4), 573-579.
(2018). Mild leukopenia following denosumab treatment in a woman with postmenopausal osteoporosis..
Endocrine. 62(2), 487-489.
(2018).
(2017).
(2015).
Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens..
Leuk Lymphoma. 58(8), 1832-1839.
(2017). Helicobacter pylori infection in patients with nonalcoholic fatty liver disease..
Metabolism. 62(1), 121-6.
(2013). Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis..
Blood. 131(14), 1568-1575.
(2018). Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma..
Haematologica. 102(3), 593-599.
(2017). Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis..
Blood Cancer J. 8(5), 46.
(2018).